Zobrazeno 1 - 3
of 3
pro vyhledávání: '"John Slemmon"'
Autor:
Jennifer Bogert, Johannes Streffer, Bart De Strooper, John Slemmon, Soraia Barão Lourenco Barao, Luc Van Nueten, Bianca Van Broeck, Marc Mercken, Leslie M. Shaw, Ina Tesseur, Katja De Waepenaert, Dieder Moechars, Sebastiaan Engelborghs, Luc Tritsmans, Maarten Timmers
Publikováno v:
Journal of Alzheimer's Disease
Journal of Alzheimer's disease
Journal of Alzheimer's disease
The β-site amyloid-β protein precursor (AβPP) cleaving enzyme-1 (BACE1) is the rate limiting enzyme in the generation of amyloid-β peptide (Aβ) from AβPP, one of the major pathways in Alzheimers disease (AD) pathology. Increased BACE1 levels an
Autor:
Marc Mercken, John Slemmon, Luc Van Nueten, Hans Stieltjes, Bianca Van Broeck, Enchi Liu, John Kemp, Maarten Timmers, Vikash K. Sinha, Jennifer Bogert, Luc Tritsmans, Katja De Waepenaert, Steven Ramael, Dieder Moechars, Sebastiaan Engelborghs, Alberto Russu, Leslie M. Shaw, Johannes Streffer
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Objectives Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, JNJ-54861911, were assessed after single and multiple dosing in healthy participants. Methods Tw
Autor:
Marc Mercken, Maarten Timmers, John Slemmon, Bianca Van Broeck, Luc Van Nueten, Jennifer Bogert, Sebastiaan Engelborghs, Leslie M. Shaw, Steven Ramael, Johannes Streffer
Publikováno v:
Alzheimer's Research & Therapy
Alzheimer's research & therapy
Alzheimer's research & therapy
Background Cerebrospinal fluid (CSF) amyloid-beta (Aβ) peptides are predictive biomarkers for Alzheimer’s disease and are proposed as pharmacodynamic markers for amyloid-lowering therapies. However, frequent sampling results in fluctuating CSF Aβ